EN
营业咨询
中国：
Email: marketing@medicilon.com.cn
营业咨询专线：400-780-8018
（仅限效劳咨询，其他事宜请拨打川沙总部电话）
川沙总部电话: +86 (21) 5859-1500
外洋：
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
尊龙凯时展位#43
第46届韩国非临床试验钻研会 (The Korean Society of Nonclinical Study, KSNS) 将于2024年10月17-18日在韩国庆尚南道举行。本次大会由韩国非临床试验研究协会（KSNS）组织，是韩国最负盛名和最具影响力的非临床研究聚会之一。届时来自生物医药手艺领域研发公司的向导者和决议者，及众多非临床研究专家们都将加入此次运动。TFM of Medicilon Chuansha Site邹汉军博士DABT将向导尊龙凯时美国团队出席此次大会，我们在展位#43，期待与您的交流！
时间 | October 17-18, 2024
所在 | Gyeongju, South Gyeongsang Province
尊龙凯时展位 | 43，不见不散！
作为海内较早为客户提供临床前动物实验的CRO公司之一，尊龙凯时具备周全的临床前研究效劳能力，能够提供系统的体内药效学和GLP条件下的药代动力学、清静性评价研究效劳。现在尊龙凯时已拥有多种稳固的药效评价模子，可对细胞毒及靶向类小分子、单抗及双特异抗体等大分子药物、ADC、CAR-T/CAR-NK细胞治疗抗肿瘤新药提供周全系统的评价。尊龙凯时对大宗化学药物和生物药物建设了系统剖析要领和体内外评价要领，包括小分子和大分子生物剖析平台、免疫剖析事情站及放射性同位素药代动力学研究平台等，支持早期筛选、成药性评价和IND申报等。尊龙凯时拥有经中国NMPA认证的GLP资质，且通过了美国FDA的GLP现场检查，具备切合国际标准的GLP系统，并且获得AAALAC认证，实验动物治理质量标准获得国际认可。至2024年6月尾，尊龙凯时已为全球超2000家客户提供药物研发效劳，加入研发完成的新药及仿制药项目已有490件IND获批临床，与海内外优质客户配合生长。
邹汉军博士 TFM of Medicilon Chuansha Site
Dr. Hanjun Zou is currently the Testing Facility Management for Medicilon Chuansha site in Shanghai. Dr. Zou joined Medicilon in March 2023 as Senior Director in which he led the team or as the study director to be responsible for the overall planning and implementation of the nonclinical study programs, including but not limited to the IND/NDA package design, selection of species, dose determination, protocol design, results interpretation, report drafting and communication with regulatory agencies. The type of drugs he supported included small molecule chemicals, peptide, fusion protein, oligonucleotide, single/bispecific antibodies, ADC, CGT product etc. Before joining Medicilon, Dr. Zou has more than 16 years of experience in toxicity and preclinical safety assessment with most career working in multinational companies. Dr. Zou is also a certified toxicologist (DCST, ERT & DABT) in China, Europe and the United States.
Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones. Medicilon's Preclinical Research Division services include the following for small molecules, biologics and medicinal herbs: Pharmacology, Pharmacodynamics, ADME, DMPK, Bioanalysis, Drug Safety Evaluation. Medicilon maintains a large in-house library of animal disease models to meet the research demands in different therapeutic areas. Medicilon can also assist clients in the preparation of a preclinical safety evaluation package.
?Tumor Animal Models (400+)
?Non-tumor Animal Models (270+)
?In Vitro ADMET
?In Vivo PK & Tox
?Single and repeated-dose toxicity studies
?Reproductive/developmental and juvenile toxicity studies
?Genotoxicity studies
?Toxicokinetic studies
?Safety pharmacology research
?Immunogenicity studies
?Local tolerance studies
?Carcinogenicity studies
相关新闻川沙总部
地点: 上海市浦东新区川亨衢585号
邮编: 201299
电话: +86 (21) 5859-1500（总机）
传真: +86 (21) 5859-6369
外洋：
Email:?marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)
